Rigel Pharmaceuticals, Inc. (RIGL) announced, overall, the company expects to report net product sales of $104.3 million in 2023, representing 36% growth over 2022. For the fourth quarter, Rigel expects to report total revenue of approximately $35.7 million. Rigel expects to report cash, cash equivalents, and short-term investments of approximately $56.9 million as of December 31, 2023.
"2023 was a year of significant growth across our commercial hematology-oncology portfolio. We grew TAVALISSE net product sales nearly 24% over 2022 and successfully achieved more than $10 million of REZLIDHIA revenue during first full year of launch. This enabled us to generate more than $104 million of total net product sales this year," said Raul Rodriguez, Rigel's CEO.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.